Ibalizumab, a monoclonal antibody for treating Multidrug resistant HIV infection

A new biologic medication – the first for HIV – is showing promise in treating patients with multidrug resistance, according to phase 3 research being presented at IDWeek 2016. Administered intravenously once every two weeks, ibalizumab is a biologic medication called a monoclonal antibody, a genetically engineered molecule that coats immune system cells to protect …

Ibalizumab, a monoclonal antibody for treating Multidrug resistant HIV infection Read More »